SCHEMBL2374577

SCHEMBL2374577

O=C(O)c1ccc(CNC(=O)c2csc(Nc3ccncn3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPL P40238 13/20 0.46
TRPV4 Q9HBA0 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.41
HPGDS O60760 1/20 0.41
ROCK2 O75116 1/20 0.40
RPS6KA5 O75582 1/20 0.40
MAP4K4 O95819 1/20 0.40
PRKCG P05129 1/20 0.40
PRKACA P17612 1/20 0.40
RPS6KB1 P23443 1/20 0.40
MAPK1 P28482 1/20 0.40
AKT1 P31749 1/20 0.40
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
PRKX P51817 1/20 0.40
PRKCD Q05655 1/20 0.40
PRKG2 Q13237 1/20 0.40
ROCK1 Q13464 1/20 0.40
DYRK1A Q13627 1/20 0.40
PRKG1 Q13976 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL669856 0.90 MMP13 (0.48) MPLSMN1; SMN2ROCK2RPS6KA5MAP4K4
SCHEMBL29072859 0.90 MMP13 (0.48) MPLSMN1; SMN2ROCK2RPS6KA5MAP4K4
SCHEMBL2373945 0.89 NAMPT (0.46) MPLTRPV4SMN1; SMN2
SCHEMBL24139180 0.88 SMN1; SMN2 (0.53) MPLTRPV4SMN1; SMN2ROCK2MAPK1
SCHEMBL2373434 0.88 TRPV4 (0.44) MPLTRPV4SMN1; SMN2MAPK1
SCHEMBL12254348 0.87 CYP1A2 (0.41) MPLTRPV4SMN1; SMN2ROCK2MAPK1
SCHEMBL2373405 0.86 CYP1A2 (0.58) SMN1; SMN2HPGDSROCK2MAPK1ROCK1
SCHEMBL2374491 0.86 NAMPT (0.48) MPLTRPV4SMN1; SMN2
SCHEMBL2373894 0.83 HTT (0.55) SMN1; SMN2ROCK2ROCK1MMP13
SCHEMBL31681851 0.83 HTT (0.55) SMN1; SMN2ROCK2ROCK1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410397-B2 Methods of enhancing cell survival of stem cells THE SCRIPPS RESEARCH INSTITUTE (US) 2025-09-09 US disclosed
EP-4585589-A2 STEM CELL CULTURES The Scripps Research Institute (US) 2025-07-16 EP disclosed
EP-4296270-B1 A COMPOSITION COMPRISING STEM CELL CULTURES SCRIPPS RESEARCH INST (US) 2025-06-18 EP disclosed
EP-4296270-A2 A COMPOSITION COMPRISING STEM CELL CULTURES The Scripps Research Institute (US) 2023-12-27 EP disclosed
EP-3936508-B1 A COMPOSITION COMPRISING STEM CELL CULTURES SCRIPPS RESEARCH INST (US) 2023-12-06 EP disclosed
EP-3936508-A1 A COMPOSITION COMPRISING STEM CELL CULTURES The Scripps Research Institute (US) 2022-01-12 EP disclosed
EP-3936508-A1 A COMPOSITION COMPRISING STEM CELL CULTURES The Scripps Research Institute (US) 2022-01-12 EP disclosed
US-20210403862-A1 METHODS OF ENHANCING CELL SURVIVAL OF STEM CELLS THE SCRIPPS RESEARCH INSTITUTE 2021-12-30 US disclosed
US-20210403862-A1 METHODS OF ENHANCING CELL SURVIVAL OF STEM CELLS THE SCRIPPS RESEARCH INSTITUTE 2021-12-30 US disclosed
EP-3623374-B1 STEM CELL CULTURES SCRIPPS RESEARCH INST (US) 2021-09-08 EP disclosed
EP-2370445-B1 STEM CELL CULTURES SCRIPPS RESEARCH INST (US) 2014-07-23 EP disclosed
EP-2370445-B1 STEM CELL CULTURES SCRIPPS RESEARCH INST (US) 2014-07-23 EP disclosed
US-20110294761-A1 STEM CELL CULTURES THE SCRIPPS RESEARCH INSTITUTE (US) 2011-12-01 US disclosed
US-20110294761-A1 STEM CELL CULTURES THE SCRIPPS RESEARCH INSTITUTE (US) 2011-12-01 US disclosed
US-20110294761-A1 STEM CELL CULTURES THE SCRIPPS RESEARCH INSTITUTE (US) 2011-12-01 US disclosed
US-8044201-B2 Stem cell cultures THE SCRIPPS RESEARCH INSTITUTE (US) 2011-10-25 US disclosed
US-8044201-B2 Stem cell cultures THE SCRIPPS RESEARCH INSTITUTE (US) 2011-10-25 US disclosed
US-20110224233-A1 STEM CELL CULTURES THE SCRIPPS RESEARCH INSTITUTE (US) 2011-09-15 US disclosed
US-20110224233-A1 STEM CELL CULTURES THE SCRIPPS RESEARCH INSTITUTE (US) 2011-09-15 US disclosed
WO-2010065721-A1 STEM CELL CULTURES THE SCRIPPS RESEARCH INSTITUTE (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294761-A1 STEM CELL CULTURES NES, CD44, MCL1 MPL 819/4885TRPV4 4274/4885SMN1; SMN2 116/4885
US-12410397-B2 Methods of enhancing cell survival of stem cells MCL1, BCL2, BCLAF1 MPL 1128/4885TRPV4 4805/4885SMN1; SMN2 14/4885
US-20210403862-A1 METHODS OF ENHANCING CELL SURVIVAL OF STEM CELLS MCL1, BCL2, BCLAF1 MPL 1128/4885TRPV4 4805/4885SMN1; SMN2 14/4885
US-20110224233-A1 STEM CELL CULTURES NES, CD44, MCL1 MPL 819/4885TRPV4 4274/4885SMN1; SMN2 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.